Pharmaceuticals, Biotechnology and Life Sciences
Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.
Data supporting the application demonstrated that the investigational subcutaneous formulation improved quality of life, reduced administration time, lowered rates of…
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human…
ViiV Healthcare and Janssen Sciences Ireland UC’s Juluca Combination Tablets for treating HIV (type 1) was approved by the Ministry…